US 12,391,738 B2
Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
Wei-Chiang Shen, San Marino, CA (US); Yuqian Liu, Henan (CN); and Hsuan-Yao Wang, Fullerton, CA (US)
Assigned to Livactus, Inc., Pasadena, CA (US)
Filed by Livactus, Inc., Pasadena, CA (US)
Filed on Aug. 25, 2022, as Appl. No. 17/895,638.
Application 17/895,638 is a continuation of application No. 16/630,322, granted, now 11,459,368, previously published as PCT/US2018/042025, filed on Jul. 13, 2018.
Claims priority of provisional application 62/532,822, filed on Jul. 14, 2017.
Prior Publication US 2022/0402993 A1, Dec. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/62 (2006.01); A61P 3/00 (2006.01); C07K 14/79 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/62 (2013.01) [A61P 3/00 (2018.01); C07K 14/79 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] 8 Claims
 
1. A method of treating insulin resistance in a subject having insulin resistance comprising administering to the subject an effective amount of a pharmaceutical composition comprising a fusion protein encoded by a nucleic acid sequence comprising a pre-proinsulin nucleic acid sequence operably linked to a transferrin (Tf) sequence and a pharmaceutically acceptable carrier, thereby treating the insulin resistance.